OncLive Fellows Forum

Kelsey Pan, MD, MPH, discusses notable presentations from an OncLive Fellows Forum on Thoracic Oncology.

Hematology/oncology fellows shared insights on notable presentations given during the OncLive Fellows Forum on Thoracic Oncology.

Tali Azenkot, MD, discusses the rationale for combining dupilumab with cemiplimab in early-stage, resectable non–small cell lung cancer.

Hyein Jeon, MD, highlights key abstracts and takeaways from an OncLive Fellows Forum on lung cancer.

A research fellow from Dana-Farber Cancer Institute shares post hoc findings from the phase 3 JAVELIN Renal 101 trial.

Chinmay Jani, MD, discusses the rate of inclusion of patient-reported outcome end points in clinical trials of patients with lung cancer.

Noha Soror, MD, discussed data from an analysis of patient-reported outcomes in from hospitalized patients with cancer.

Robert Cameron, MD, PhD, discusses a study examining the impact of PD-L1 expression on outcomes with osimertinib in EGFR-mutated NSCLC.

Mitchell Parma, MD, discusses an analysis of survival benefit with immunotherapy in patients with NSCLC brain metastases.

Tess O’Meara, MD, MHS, and Kelsey H. Natsuhara, MD, discuss their presentations from the OncLive National Fellows Forum at SABCS.

Oncology fellows with aspirations of entering the lung cancer field gathered in Chicago, Illinois, to share findings from their research, network, and participate in panel discussions featuring expert faculty